HL156A

HL156A
Clinical data
Other namesIM156, HL271 acetate, UNII-4G3BUV6ZSK
Identifiers
  • N'-[N'-[4-(trifluoromethoxy)phenyl]carbamimidoyl]pyrrolidine-1-carboximidamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H16F3N5O
Molar mass315.300 g·mol−1
3D model (JSmol)
  • C1CCN(C1)C(=NC(=NC2=CC=C(C=C2)OC(F)(F)F)N)N
  • InChI=1S/C13H16F3N5O/c14-13(15,16)22-10-5-3-9(4-6-10)19-11(17)20-12(18)21-7-1-2-8-21/h3-6H,1-2,7-8H2,(H4,17,18,19,20)
  • Key:NGFUHJWVBKTNOE-UHFFFAOYSA-N

HL156A is an experimental drug being studied for its potential use in cancer treatment. Chemically, it is derivative of metformin and a potent oxidative phosphorylation inhibitor and AMP-activated protein kinase activating biguanide. Certain types of cancer cells requires oxidative phosphorylation to survive. By targeting it, HL156A might help in improving anticancer therapy. It is more potent than acadesine or metformin at activating AMP-activated protein kinase. It is being developed by Hanall Biopharma.

Research

HL156A is in phase 1 clinical trials in patients with advanced solid tumor and lymphoma. It is also being studied in other conditions such as liver and renal fibrosis, cancer and drug resistance in cancer. HL176OUT04, a drug with similar pharmacology, has been also developed.

Pharmacology

Apart from AMP-activated protein kinase activation, it also inhibits expression and activation of insulin-like growth factor-1, protein kinase B, mammalian target of rapamycin (mTOR), and extracellular signal-regulated kinases.

See also